
Tradewind BioScience creates transformative drugs targeting aggressive cancers.
Tradewind BioScience was founded with the mission to develop transformative drugs targeting the most aggressive human cancers. The company's vision is to make a significant difference in patients' lives by creating innovative therapies that not only target primary cancer cells but also enhance the immune system's natural anti-cancer functions. Their lead product is a multifaceted attack antibody designed specifically for ovarian cancer, aiming to provide a comprehensive therapeutic approach.
Notable affiliated people and investors include leading scientists and industry experts dedicated to advancing cancer treatment. Tradewind BioScience has achieved significant milestones, including the development of their lead candidate for ovarian cancer, which exemplifies their science-driven approach. The impact of their work is profound, offering new hope and potentially life-saving treatments for patients battling some of the most challenging forms of cancer.

Trio Pharmaceuticals

Fresh Wind Biotechnologies USA
SunnyBay BioTech

OncoResponse

Treadwell Therapeutics
treadwelltx.com

Asher Bio
asherbio.com

Angarus Therapeutics
angarustx.com

Guardian Bio
guardian-bio.com

Valink Therapeutics
valinktx.com

Adventris Pharmaceuticals
adventris.com

Granza Bio
granzabio.com

Oncobox
oncobox.com

Meditope Biosciences
meditope.com

Alixia
alixia.com

Window Therapeutics
windowtx.com
Companies similar to Tradewind BioScience include Trio Pharmaceuticals, Fresh Wind Biotechnologies USA, SunnyBay BioTech and OncoResponse.
Tradewind BioScience was founded in 2017.
Tradewind BioScience's headquarters is located in South San Francisco, CA, US.
Tradewind BioScience's most recent funding round was for $120k (USD) in January 2018.
As of Jan 4, 2018, Tradewind BioScience has disclosed funding of $120k (USD). Undisclosed round amounts are excluded.
Tradewind BioScience has 7 employees as of Feb 4, 2024.